Form 4: DexCom Director Receives RSU Grant

DexCom Director Richard Alexander Collins was granted 5,605 restricted stock units as part of his compensation.

Summary

• Director Richard Alexander Collins received an award of 5,605 restricted stock units (RSUs) on May 28, 2026.
• The RSUs represent a contingent right to receive one share of DexCom, Inc. common stock per unit upon settlement.
• The award is scheduled to vest fully on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSU award is expected to vest in full by the 2027 Annual Meeting of Stockholders or the one-year anniversary of the grant date.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure alignment between board members and shareholders in the medical device sector.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with standard practices among large-cap healthcare and technology companies.
• The vesting schedule is typical for annual director equity awards.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the RSU award on or before the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

DexCom, DXCM, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units